Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of regorafenib in participants from prior Bayer-sponsored regorafenib trials (Japan)
jRCT1080224680Phase 4Completed
- Sponsor
- Bayer
- Start
- May 2019
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of regorafenib in Nonhematologic neoplasms and cancer, sponsored by Bayer. Started May 2019; status: completed.
02
Drugs
regorafenib
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on jRCT1080224680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224680.